Sanofi ROA 2010-2024 | SNY

Current and historical return on assets (ROA) values for Sanofi (SNY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Sanofi ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2024-03-31 $4.93B $0.00B 7.21%
2023-12-31 $5.84B $136.87B 8.55%
2023-09-30 $9.68B $0.00B 14.33%
2023-06-30 $9.02B $136.69B 13.35%
2023-03-31 $8.71B $0.00B 13.23%
2022-12-31 $8.82B $133.51B 13.41%
2022-09-30 $8.33B $0.00B 25.69%
2022-03-31 $6.88B $0.00B 20.32%
2021-09-30 $6.90B $0.00B 20.40%
2021-03-31 $7.99B $0.00B inf%
2020-09-30 $7.39B $0.00B inf%
2020-03-31 $6.36B $0.00B inf%
2019-09-30 $4.98B $0.00B 17.65%
2019-03-31 $4.86B $0.00B 17.22%
2018-03-31 $4.71B $0.00B 8.37%
2017-12-31 $9.53B $112.83B 16.96%
2017-09-30 $9.90B $0.00B 17.37%
2017-06-30 $9.92B $112.08B 17.41%
2017-03-31 $10.09B $0.00B 17.71%
2016-12-31 $5.21B $115.83B 9.15%
2016-09-30 $6.19B $0.00B 22.10%
2016-06-30 $5.76B $111.96B 10.46%
2016-03-31 $5.52B $0.00B 9.48%
2015-09-30 $4.90B $0.00B 5.45%
2015-06-30 $4.59B $108.32B 3.75%
2014-06-30 $5.57B $124.45B 5.83%
2013-06-30 $6.39B $126.66B 6.44%
2012-06-30 $8.61B $130.75B 12.74%
2012-03-31 $8.56B $0.00B 12.10%
2011-12-31 $9.33B $139.51B 13.20%
2011-09-30 $8.04B $0.00B 12.53%
2011-06-30 $7.45B $143.31B 11.62%
2011-03-31 $8.22B $0.00B 14.73%
2010-12-31 $8.24B $113.22B 14.76%
2010-09-30 $9.30B $0.00B 16.78%
2010-06-30 $10.37B $110.06B 18.71%
2010-03-31 $11.38B $0.00B 21.05%
2009-12-31 $10.99B $111.64B 20.34%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $118.520B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $842.050B 121.70
Novo Nordisk (NVO) Denmark $632.697B 48.62
Johnson & Johnson (JNJ) United States $355.659B 14.13
Merck (MRK) United States $328.429B 59.76
AbbVie (ABBV) United States $303.959B 15.70
AstraZeneca (AZN) United Kingdom $243.573B 21.17
Novartis AG (NVS) Switzerland $216.133B 15.32
Pfizer (PFE) United States $157.191B 19.53
Innoviva (INVA) United States $1.003B 7.05